BioCryst Pharmaceuticals (BCRX) recently issued full year 2026 earnings guidance, telling investors it expects total revenue between US$635 million and US$660 million, a data point that now anchors many discussions around the stock.

Even with the fresh 2026 revenue guidance and a slot at the J.P. Morgan Healthcare Conference, BioCryst Pharmaceuticals’ recent trading has been weak, with a 1 day share price return of 7.11% and a 7 day share price return of 10.00%, while the 1 year total shareholder return of 10.60% and 3 year total shareholder return of 35.96% point to pressure on longer term holders.

If this kind of earnings guidance has you rethinking your biotech exposure, it could be a good moment to scan other healthcare stocks that fit your risk and return preferences.

With 2026 revenue guidance set at US$635 million to US$660 million and the share price at US$6.66 after weak recent returns, is BioCryst now trading below its fundamentals, or is the market already pricing in future growth?

Most Popular Narrative: 67.7% Undervalued

The most followed narrative on BioCryst sets a fair value of US$20.60 against the last close at US$6.66, framing a wide gap that all hinges on how rare disease revenues, margins and future cash flows play out over the next few years.

Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins. Anticipated approval and launch of new indications, such as ORLADEYO granules for pediatric patients and expanded use in HAE with normal C1 inhibitor, broadens the addressable market in an environment of growing global healthcare spending on rare disease therapies, which should further increase long-term revenues and earnings visibility.

Want to see what kind of revenue curve, margin shift and future earnings multiple are baked into that valuation gap? The full narrative spells out the numbers and the timing behind them.

Result: Fair Value of $20.60 (UNDERVALUED)

However, this hinges on ORLADEYO holding its ground in a crowded hereditary angioedema market, and on early stage pipeline programs clearing key clinical and regulatory hurdles.

Build Your Own BioCryst Pharmaceuticals Narrative

If you see the numbers differently or prefer to dig into the details yourself, you can build a custom view in just a few minutes, starting with Do it your way.

A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If BioCryst has your attention, do not stop here. Use the Simply Wall St Screener to spot fresh ideas that match how you like to invest.

• Target potential value gaps by scanning these 863 undervalued stocks based on cash flows that might align more closely with the prices you are willing to pay.
• Ride emerging tech trends by checking out these 24 AI penny stocks that are tying artificial intelligence to real business models.
• Boost your income focus by reviewing these 12 dividend stocks with yields > 3% offering yields above 3% that could support a more consistent return profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.